Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: a 18-month prospective clinical trial
Li Y, Fu R, Gao J, Wang L, Duan Z, Tian L, Ge H, Ma X, Zhang Y, Li K, Xu P, Tian X, Chen Z. Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: a 18-month prospective clinical trial. Scientific Reports 2022, 12: 255. PMID: 34996948, PMCID: PMC8742122, DOI: 10.1038/s41598-021-03691-0.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAdministration, OralAdultDisease ProgressionDrug TaperingDrug Therapy, CombinationFemaleGlomerulonephritis, IGAGlucocorticoidsHumansKidney Failure, ChronicMaleMethylprednisolonePrednisoneProspective StudiesProteinuriaPulse Therapy, DrugRemission InductionRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsLow-dose prednisoneComplete remissionFP groupIntravenous methylprednisoloneHigh-risk IgA nephropathyOxford MEST-C scoreChinese Clinical Trial RegistryPulsed intravenous methylprednisoloneACEI/ARBClinical Trials RegistryProspective clinical trialsMEST-C scoreFavorable safety profilePercentage of CROral prednisoneTotal remissionAdult patientsNephropathy patientsPrednisone regimenCushing's syndromeMore patientsPrimary outcomeTrials RegistryClinical outcomesIgA nephropathy